{
    "clinical_study": {
        "@rank": "153233", 
        "brief_summary": {
            "textblock": "To determine the safety and anti-HIV activity of two doses of SC-49483 in combination with\n      zidovudine (AZT) versus AZT alone. To determine the influences of viral phenotype on the\n      anti-HIV activity of these treatment regimens.\n\n      SC-49483 has no inherent activity against HIV-1 but is converted in the intestinal wall to\n      SC-48334, which has demonstrated anti-HIV activity. Since SC-49483 causes significantly less\n      gastrointestinal toxicity than SC-48334, the combination of SC-49483 with AZT may improve\n      the benefits of both drugs in patients with HIV infection."
        }, 
        "brief_title": "A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV", 
        "completion_date": {
            "#text": "July 1995", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "SC-49483 has no inherent activity against HIV-1 but is converted in the intestinal wall to\n      SC-48334, which has demonstrated anti-HIV activity. Since SC-49483 causes significantly less\n      gastrointestinal toxicity than SC-48334, the combination of SC-49483 with AZT may improve\n      the benefits of both drugs in patients with HIV infection.\n\n      Patients are randomized to receive AZT alone or in combination with one of two doses of\n      SC-49483, administered three times daily. Treatment continues for 16 to 24 weeks. Per\n      07/19/94 amendment: At the end of 24 weeks, blinded treatment continues for an additional 4\n      weeks, at which time patients may receive open-label drug on an optional basis for 90 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Required:\n\n          -  PCP prophylaxis (trimethoprim/sulfamethoxazole, dapsone, or aerosolized pentamidine)\n             in patients with CD4 count <= 200 cells/mm3.\n\n        Allowed:\n\n          -  Topical antifungal agents, ketoconazole, fluconazole, and itraconazole for\n             candidiasis or disseminated fungal infections, as medically indicated.\n\n          -  Maintenance therapy for Mycobacteria disease with isoniazid, ethambutol, rifampin,\n             pyrazinamide, clofazimine, ciprofloxacin, clarithromycin, or rifabutin.\n\n          -  Maintenance therapy for toxoplasmosis with pyrimethamine, sulfadiazine, or\n             clindamycin.\n\n          -  Maintenance therapy for herpes simplex virus with acyclovir at <= 1000 mg/day.\n\n          -  Recombinant erythropoietin and G-CSF, if indicated.\n\n          -  Antibiotics for bacterial infections.\n\n          -  Symptomatic treatment such as antipyretics, analgesics, nonsteroidal\n             anti-inflammatory agents, and antiemetics.\n\n        Concurrent Treatment:\n\n        Allowed:\n\n          -  Localized radiation therapy and limited intralesional therapy for cutaneous Kaposi's\n             sarcoma.\n\n        Patients must have:\n\n          -  Documented HIV infection.\n\n          -  Per 07/19/94 amendment, one of the following:\n\n          -  CD4 count 150 - 350 cells/mm3 within 60 days prior to study entry AND prior AZT for\n             no more than 12 months cumulative (given with or without ddI or ddC).\n\n          -  CD4 count 50 - 350 cells/mm3 within 60 days prior to study entry AND no prior\n             antiretroviral therapy.\n\n          -  MT-2 cell assay within 60 days prior to study entry.\n\n        NOTE:\n\n          -  Minimal Kaposi's sarcoma is permitted.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following condition are excluded:\n\n          -  Malignancy other than minimal Kaposi's sarcoma.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Antiretroviral therapies (other than study drug).\n\n          -  Biologic response modifiers.\n\n          -  Systemic corticosteroids for > 21 consecutive days.\n\n          -  Foscarnet.\n\n          -  Systemic cytotoxic chemotherapy for a malignancy.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of cataracts.\n\n          -  History of intolerance to AZT at <= 600 mg/day.\n\n          -  Unexplained temperature >= 38.5 degrees C that persists for any 7 days within the 30\n             days prior to study entry.\n\n          -  Chronic diarrhea (defined as >= 3 stools per day) that persists for any 15 days\n             within the 30 days prior to study entry.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  More than 6 months (more than 12 months per 07/19/94 amendment) cumulative prior\n             therapy with AZT.\n\n          -  Prior induction or maintenance therapy with foscarnet.\n\n          -  Any investigational drug within 30 days prior to study entry.\n\n          -  Prior SC-49483 or SC-48334.\n\n          -  Prior ddC, ddI, or stavudine (d4T) as monotherapy.\n\n          -  Interferon or interleukin within 30 days prior to study entry.\n\n          -  Prior non-nucleoside reverse transcriptase inhibitors (e.g., NVP, ATV).\n\n          -  Systemic corticosteroids for > 21 consecutive days.\n\n          -  Acute treatment for a serious infection or any opportunistic infection within 14 days\n             prior to study entry.\n\n          -  Prior combination therapy with AZT, ddI, and/or ddC within 30 days prior to study\n             entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "210", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000791", 
            "org_study_id": "ACTG 259", 
            "secondary_id": "11236"
        }, 
        "intervention": [
            {
                "intervention_name": "Glycovir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Zidovudine"
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Antiviral Agents", 
            "Zidovudine"
        ], 
        "lastchanged_date": "April 2, 2012", 
        "link": {
            "description": "Click here for more information about Zidovudine", 
            "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=4"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }, 
                    "name": "Alabama Therapeutics CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "USC CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palo Alto", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Stanford CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "Ucsf Aids Crs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado"
                    }, 
                    "name": "University of Colorado Hospital CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Univ. of Miami AIDS CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }, 
                    "name": "Cook County Hosp. CORE Ctr."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush Univ. Med. Ctr. ACTG CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60640"
                    }, 
                    "name": "Weiss Memorial Hosp."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana"
                    }, 
                    "name": "Indiana Univ. School of Medicine, Infectious Disease Research Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana"
                    }, 
                    "name": "Methodist Hosp. of Indiana"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63112"
                    }, 
                    "name": "St. Louis ConnectCare, Infectious Diseases Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "Washington U CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14260"
                    }, 
                    "name": "SUNY - Buffalo, Erie County Medical Ctr."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Beth Israel Med. Ctr. (Mt. Sinai)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Univ. of Rochester ACTG CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27514"
                    }, 
                    "name": "Unc Aids Crs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Wake County Health and Human Services CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Univ. of Cincinnati CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Hosp. of the Univ. of Pennsylvania CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "University of Washington AIDS CRS"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV", 
        "overall_official": [
            {
                "last_name": "Fischl MA", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Saag M", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "reference": {
            "citation": "Johnson VA, Bassett RL, Stanley KE, Saag MS, Fischl MA. Predictors of syncytium-inducing viral phenotype in a phase II double-blind trial of SC-49483 plus ZDV vs. ZDV. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:102 (abstract no 205)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000791"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "G D Searle", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Glaxo Wellcome", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2012"
    }, 
    "geocoordinates": {
        "Alabama Therapeutics CRS": "33.521 -86.802", 
        "Beth Israel Med. Ctr. (Mt. Sinai)": "40.714 -74.006", 
        "Cook County Hosp. CORE Ctr.": "41.878 -87.63", 
        "Hosp. of the Univ. of Pennsylvania CRS": "39.952 -75.164", 
        "Indiana Univ. School of Medicine, Infectious Disease Research Clinic": "39.769 -86.158", 
        "Methodist Hosp. of Indiana": "39.769 -86.158", 
        "Northwestern University CRS": "41.878 -87.63", 
        "Rush Univ. Med. Ctr. ACTG CRS": "41.878 -87.63", 
        "SUNY - Buffalo, Erie County Medical Ctr.": "42.886 -78.878", 
        "St. Louis ConnectCare, Infectious Diseases Clinic": "38.627 -90.199", 
        "Stanford CRS": "37.442 -122.143", 
        "USC CRS": "34.052 -118.244", 
        "Ucsf Aids Crs": "37.775 -122.419", 
        "Unc Aids Crs": "35.913 -79.056", 
        "Univ. of Cincinnati CRS": "39.103 -84.512", 
        "Univ. of Miami AIDS CRS": "25.789 -80.226", 
        "Univ. of Rochester ACTG CRS": "43.161 -77.611", 
        "University of Colorado Hospital CRS": "39.729 -104.832", 
        "University of Washington AIDS CRS": "47.606 -122.332", 
        "Wake County Health and Human Services CRS": "35.772 -78.639", 
        "Washington U CRS": "38.627 -90.199", 
        "Weiss Memorial Hosp.": "41.878 -87.63"
    }
}